BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghigo A, Li M, Hirsch E. New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochim Biophys Acta 2016;1863:1916-25. [PMID: 26828775 DOI: 10.1016/j.bbamcr.2016.01.021] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 15.3] [Reference Citation Analysis]
Number Citing Articles
1 Golforoush PA, Narasimhan P, Chaves-Guerrero PP, Lawrence E, Newton G, Yan R, Harding SE, Perrior T, Chapman KL, Schneider MD. Selective protection of human cardiomyocytes from anthracycline cardiotoxicity by small molecule inhibitors of MAP4K4. Sci Rep 2020;10:12060. [PMID: 32694738 DOI: 10.1038/s41598-020-68907-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Pecoraro M, Ciccarelli M, Fiordelisi A, Iaccarino G, Pinto A, Popolo A. Diazoxide Improves Mitochondrial Connexin 43 Expression in a Mouse Model of Doxorubicin-Induced Cardiotoxicity. Int J Mol Sci 2018;19:E757. [PMID: 29518932 DOI: 10.3390/ijms19030757] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
3 Li Q, Qin M, Li T, Gu Z, Tan Q, Huang P, Ren L. Rutin protects against pirarubicin-induced cardiotoxicity by adjusting microRNA-125b-1-3p-mediated JunD signaling pathway. Mol Cell Biochem 2020;466:139-48. [PMID: 32016695 DOI: 10.1007/s11010-020-03696-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Diviani D, Osman H, Reggi E. A-Kinase Anchoring Protein-Lbc: A Molecular Scaffold Involved in Cardiac Protection. J Cardiovasc Dev Dis 2018;5:E12. [PMID: 29419761 DOI: 10.3390/jcdd5010012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
5 Volodina YL, Dezhenkova LG, Tikhomirov AS, Tatarskiy VV, Kaluzhny DN, Moisenovich AM, Moisenovich MM, Isagulieva AK, Shtil AA, Tsvetkov VB, Shchekotikhin AE. New anthra[2,3-b]furancarboxamides: A role of positioning of the carboxamide moiety in antitumor properties. European Journal of Medicinal Chemistry 2019;165:31-45. [DOI: 10.1016/j.ejmech.2018.12.068] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
6 Sharma A, Parikh M, Shah H, Gandhi T. Modulation of Nrf2 by quercetin in doxorubicin-treated rats. Heliyon 2020;6:e03803. [PMID: 32337383 DOI: 10.1016/j.heliyon.2020.e03803] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
7 Manolis AA, Manolis TA, Mikhailidis DP, Manolis AS. Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies - part 1. Expert Opin Drug Saf 2018;17:875-92. [PMID: 30126304 DOI: 10.1080/14740338.2018.1513488] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
8 Mattila M, Söderström M, Ailanen L, Savontaus E, Savontaus M. The Effects of Neuropeptide Y Overexpression on the Mouse Model of Doxorubicin-Induced Cardiotoxicity. Cardiovasc Toxicol 2020;20:328-38. [PMID: 31811615 DOI: 10.1007/s12012-019-09557-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Rocca C, Pasqua T, Cerra MC, Angelone T. Cardiac Damage in Anthracyclines Therapy: Focus on Oxidative Stress and Inflammation. Antioxid Redox Signal 2020;32:1081-97. [PMID: 31928066 DOI: 10.1089/ars.2020.8016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
10 Pokrzywinski KL, Biel TG, Rosen ET, Bonanno JL, Aryal B, Mascia F, Moshkelani D, Mog S, Rao VA. Doxorubicin-induced cardiotoxicity is suppressed by estrous-staged treatment and exogenous 17β-estradiol in female tumor-bearing spontaneously hypertensive rats. Biol Sex Differ 2018;9:25. [PMID: 29907135 DOI: 10.1186/s13293-018-0183-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
11 Gumà A, Díaz-Sáez F, Camps M, Zorzano A. Neuregulin, an Effector on Mitochondria Metabolism That Preserves Insulin Sensitivity. Front Physiol 2020;11:696. [PMID: 32655416 DOI: 10.3389/fphys.2020.00696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Berecz T, Yiu A, Vittay O, Orsolits B, Mioulane M, Dos Remedios CG, Ketteler R, Merkely B, Apáti Á, Harding SE, Hellen N, Foldes G. Transcriptional co-activators YAP1-TAZ of Hippo signalling in doxorubicin-induced cardiomyopathy. ESC Heart Fail 2021. [PMID: 34931757 DOI: 10.1002/ehf2.13756] [Reference Citation Analysis]
13 Caso S, Maric D, Arambasic M, Cotecchia S, Diviani D. AKAP-Lbc mediates protection against doxorubicin-induced cardiomyocyte toxicity. Biochim Biophys Acta Mol Cell Res 2017;1864:2336-46. [PMID: 28923249 DOI: 10.1016/j.bbamcr.2017.09.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
14 Christidi E, Huang HM, Brunham LR. CRISPR/Cas9-mediated genome editing in human stem cell-derived cardiomyocytes: Applications for cardiovascular disease modelling and cardiotoxicity screening. Drug Discov Today Technol 2018;28:13-21. [PMID: 30205876 DOI: 10.1016/j.ddtec.2018.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
15 Octavia Y, Kararigas G, de Boer M, Chrifi I, Kietadisorn R, Swinnen M, Duimel H, Verheyen FK, Brandt MM, Fliegner D, Cheng C, Janssens S, Duncker DJ, Moens AL. Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase. J Cell Mol Med 2017;21:3277-87. [PMID: 28608983 DOI: 10.1111/jcmm.13231] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
16 Botnariuc I, Ilie SM, Trifanescu OG, Bacinschi XE, Curea F, Anghel RM. PREDICTIVE CIRCULATING MARKERS FOR ANTHRACYCLINE CHEMOTHERAPY IN NON-METASTATIC BREAST CANCER. Acta Endocrinol (Buchar) 2017;13:209-14. [PMID: 31149175 DOI: 10.4183/aeb.2017.209] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Liu G, Liu Z, Cao N. Human pluripotent stem cell–based cardiovascular disease modeling and drug discovery. Pflugers Arch - Eur J Physiol 2021;473:1087-97. [DOI: 10.1007/s00424-021-02542-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Kim J, Cho S, Kang S, Yoo SW, Kwon SY, Min J, Bom H, Song H. Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity. J Nucl Cardiol 2020;27:2154-63. [DOI: 10.1007/s12350-019-01617-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
19 Tang H, Tao A, Song J, Liu Q, Wang H, Rui T. Doxorubicin-induced cardiomyocyte apoptosis: Role of mitofusin 2. Int J Biochem Cell Biol 2017;88:55-9. [PMID: 28483668 DOI: 10.1016/j.biocel.2017.05.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
20 Li Q, Qin M, Tan Q, Li T, Gu Z, Huang P, Ren L. MicroRNA-129-1-3p protects cardiomyocytes from pirarubicin-induced apoptosis by down-regulating the GRIN2D-mediated Ca2+ signalling pathway. J Cell Mol Med 2020;24:2260-71. [PMID: 31957170 DOI: 10.1111/jcmm.14908] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Riccio G, Antonucci S, Coppola C, D'Avino C, Piscopo G, Fiore D, Maurea C, Russo M, Rea D, Arra C, Condorelli G, Di Lisa F, Tocchetti CG, De Lorenzo C, Maurea N. Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production. Front Physiol 2018;9:38. [PMID: 29467663 DOI: 10.3389/fphys.2018.00038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
22 Sadek I, Keaton M, Maihle NJ, Tang SC. Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity. Genes Dis 2017;4:159-62. [PMID: 30258918 DOI: 10.1016/j.gendis.2017.07.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
23 Kopeva KV, Grakova EV, Shilov SN, Berezikova EN, Popova AA, Neupokoeva MN, Ratushnyak ET, Teplyakov AT. Anthracycline-induced cardiotoxicity in women without cardiovascular diseases: molecular and genetic predictors. Acta Cardiol 2021;:1-10. [PMID: 34783301 DOI: 10.1080/00015385.2021.2003061] [Reference Citation Analysis]
24 Varricchi G, Ameri P, Cadeddu C, Ghigo A, Madonna R, Marone G, Mercurio V, Monte I, Novo G, Parrella P, Pirozzi F, Pecoraro A, Spallarossa P, Zito C, Mercuro G, Pagliaro P, Tocchetti CG. Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. Front Physiol 2018;9:167. [PMID: 29563880 DOI: 10.3389/fphys.2018.00167] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 13.3] [Reference Citation Analysis]
25 Li R, Huang Y, Semple I, Kim M, Zhang Z, Lee JH. Cardioprotective roles of sestrin 1 and sestrin 2 against doxorubicin cardiotoxicity. Am J Physiol Heart Circ Physiol 2019;317:H39-48. [PMID: 31026186 DOI: 10.1152/ajpheart.00008.2019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
26 Wang Y, Zhang Y, Sun B, Tong Q, Ren L. Rutin Protects against Pirarubicin-Induced Cardiotoxicity through TGF-β1-p38 MAPK Signaling Pathway. Evid Based Complement Alternat Med 2017;2017:1759385. [PMID: 28367221 DOI: 10.1155/2017/1759385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
27 McSweeney KM, Bozza WP, Alterovitz WL, Zhang B. Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity. Cell Death Discov 2019;5:102. [PMID: 31231550 DOI: 10.1038/s41420-019-0182-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
28 Gulluni F, Martini M, De Santis MC, Campa CC, Ghigo A, Margaria JP, Ciraolo E, Franco I, Ala U, Annaratone L, Disalvatore D, Bertalot G, Viale G, Noatynska A, Compagno M, Sigismund S, Montemurro F, Thelen M, Fan F, Meraldi P, Marchiò C, Pece S, Sapino A, Chiarle R, Di Fiore PP, Hirsch E. Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding Function. Cancer Cell 2017;32:444-459.e7. [DOI: 10.1016/j.ccell.2017.09.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
29 Li M, Sala V, De Santis MC, Cimino J, Cappello P, Pianca N, Di Bona A, Margaria JP, Martini M, Lazzarini E, Pirozzi F, Rossi L, Franco I, Bornbaum J, Heger J, Rohrbach S, Perino A, Tocchetti CG, Lima BH, Teixeira MM, Porporato PE, Schulz R, Angelini A, Sandri M, Ameri P, Sciarretta S, Lima-júnior RCP, Mongillo M, Zaglia T, Morello F, Novelli F, Hirsch E, Ghigo A. Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth. Circulation 2018;138:696-711. [DOI: 10.1161/circulationaha.117.030352] [Cited by in Crossref: 68] [Cited by in F6Publishing: 36] [Article Influence: 17.0] [Reference Citation Analysis]
30 Audebrand A, Désaubry L, Nebigil CG. Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments. Front Cardiovasc Med 2019;6:194. [PMID: 32039239 DOI: 10.3389/fcvm.2019.00194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Bellin M, Mummery CL. The cancer's gone, but did chemotherapy damage your heart? Nat Rev Cardiol 2016;13:383-4. [DOI: 10.1038/nrcardio.2016.88] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
32 Jantas D, Gręda A, Gołda S, Korostyński M, Lasoń W. The neuroprotective effects of orthosteric agonists of group II and III mGluRs in primary neuronal cell cultures are dependent on developmental stage. Neuropharmacology 2016;111:195-211. [PMID: 27600687 DOI: 10.1016/j.neuropharm.2016.09.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
33 Bini I, Asaftei SD, Riggi C, Tirtei E, Manicone R, Biasin E, Basso ME, Agnoletti G, Fagioli F. Anthracycline-induced cardiotoxicity in patients with paediatric bone sarcoma and soft tissue sarcoma. Cardiol Young 2017;27:1815-22. [PMID: 28780919 DOI: 10.1017/S1047951117001536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
34 Wang T, Jiang Y, Chu H, Liu X, Dai Y, Wang D. Doxorubicin and Lovastatin co-delivery liposomes for synergistic therapy of liver cancer. Journal of Drug Delivery Science and Technology 2019;52:452-9. [DOI: 10.1016/j.jddst.2019.04.045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
35 Li M, Russo M, Pirozzi F, Tocchetti CG, Ghigo A. Autophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunities. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2020;1867:118493. [DOI: 10.1016/j.bbamcr.2019.06.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
36 Iguchi N, Dönmez Mİ, Carrasco A Jr, Wilcox DT, Pineda RH, Malykhina AP, Cost NG. Doxorubicin induces detrusor smooth muscle impairments through myosin dysregulation, leading to a risk of lower urinary tract dysfunction. Am J Physiol Renal Physiol 2019;317:F197-206. [PMID: 31066574 DOI: 10.1152/ajprenal.00090.2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Koczurkiewicz-Adamczyk P, Klaś K, Gunia-Krzyżak A, Piska K, Andrysiak K, Stępniewski J, Lasota S, Wójcik-Pszczoła K, Dulak J, Madeja Z, Pękala E. Cinnamic Acid Derivatives as Cardioprotective Agents against Oxidative and Structural Damage Induced by Doxorubicin. Int J Mol Sci 2021;22:6217. [PMID: 34207549 DOI: 10.3390/ijms22126217] [Reference Citation Analysis]
38 Kalyanaraman B. Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? Redox Biol 2020;29:101394. [PMID: 31790851 DOI: 10.1016/j.redox.2019.101394] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 15.0] [Reference Citation Analysis]
39 Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep 2017;7:44735. [PMID: 28300219 DOI: 10.1038/srep44735] [Cited by in Crossref: 104] [Cited by in F6Publishing: 105] [Article Influence: 20.8] [Reference Citation Analysis]
40 Shimauchi T, Numaga-Tomita T, Ito T, Nishimura A, Matsukane R, Oda S, Hoka S, Ide T, Koitabashi N, Uchida K, Sumimoto H, Mori Y, Nishida M. TRPC3-Nox2 complex mediates doxorubicin-induced myocardial atrophy. JCI Insight 2017;2:93358. [PMID: 28768915 DOI: 10.1172/jci.insight.93358] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
41 Mancilla TR, Davis LR, Aune GJ. Doxorubicin-induced p53 interferes with mitophagy in cardiac fibroblasts. PLoS One 2020;15:e0238856. [PMID: 32960902 DOI: 10.1371/journal.pone.0238856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 El-Far AH, Godugu K, Salaheldin TA, Darwish NHE, Saddiq AA, Mousa SA. Nanonutraceuticals: Anti-Cancer Activity and Improved Safety of Chemotherapy by Costunolide and Its Nanoformulation against Colon and Breast Cancer. Biomedicines 2021;9:990. [PMID: 34440193 DOI: 10.3390/biomedicines9080990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zhao L, Qi Y, Xu L, Tao X, Han X, Yin L, Peng J. MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2. Redox Biol 2018;15:284-96. [PMID: 29304479 DOI: 10.1016/j.redox.2017.12.013] [Cited by in Crossref: 75] [Cited by in F6Publishing: 85] [Article Influence: 15.0] [Reference Citation Analysis]
44 Holmgren G, Synnergren J, Andersson CX, Lindahl A, Sartipy P. MicroRNAs as potential biomarkers for doxorubicin-induced cardiotoxicity. Toxicol In Vitro 2016;34:26-34. [PMID: 27033315 DOI: 10.1016/j.tiv.2016.03.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
45 Pereira JD, Tosatti JAG, Simões R, Luizon MR, Gomes KB, Alves MT. microRNAs associated to anthracycline-induced cardiotoxicity in women with breast cancer: A systematic review and pathway analysis. Biomedicine & Pharmacotherapy 2020;131:110709. [DOI: 10.1016/j.biopha.2020.110709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
46 Leerink JM, van de Ruit M, Feijen EAM, Kremer LCM, Mavinkurve-Groothuis AMC, Pinto YM, Creemers EE, Kok WEM. Extracellular matrix remodeling in animal models of anthracycline-induced cardiomyopathy: a meta-analysis. J Mol Med (Berl) 2021;99:1195-207. [PMID: 34052857 DOI: 10.1007/s00109-021-02098-8] [Reference Citation Analysis]
47 Modesto PN, Polegato BF, Dos Santos PP, Grassi LDV, Molina LCC, Bazan SGZ, Pereira EJ, Fernandes AAH, Fabro AT, Androcioli VN, Roscani MG, de Paiva SAR, Zornoff LAM, Minicucci MF, Azevedo PS. Green Tea (Camellia sinensis) Extract Increased Topoisomerase IIβ, Improved Antioxidant Defense, and Attenuated Cardiac Remodeling in an Acute Doxorubicin Toxicity Model. Oxid Med Cell Longev 2021;2021:8898919. [PMID: 34035878 DOI: 10.1155/2021/8898919] [Reference Citation Analysis]
48 Milano G, Biemmi V, Lazzarini E, Balbi C, Ciullo A, Bolis S, Ameri P, Di Silvestre D, Mauri P, Barile L, Vassalli G. Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity. Cardiovasc Res 2020;116:383-92. [PMID: 31098627 DOI: 10.1093/cvr/cvz108] [Cited by in Crossref: 27] [Cited by in F6Publishing: 36] [Article Influence: 13.5] [Reference Citation Analysis]
49 Osataphan N, Phrommintikul A, Chattipakorn SC, Chattipakorn N. Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: Insights for future interventions. J Cell Mol Med 2020;24:6534-57. [PMID: 32336039 DOI: 10.1111/jcmm.15305] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
50 Afrin H, Salazar CJ, Kazi M, Ahamad SR, Alharbi M, Nurunnabi M. Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.01.011] [Reference Citation Analysis]
51 Cagel M, Grotz E, Bernabeu E, Moretton MA, Chiappetta DA. Doxorubicin: nanotechnological overviews from bench to bedside. Drug Discovery Today 2017;22:270-81. [DOI: 10.1016/j.drudis.2016.11.005] [Cited by in Crossref: 144] [Cited by in F6Publishing: 136] [Article Influence: 28.8] [Reference Citation Analysis]
52 Alves MT, Simões R, Pestana RMC, de Oliveira AN, Oliveira HHM, Soares CE, Sabino AP, Silva LM, Gomes KB. Interleukin-10 Levels are Associated with Doxorubicin-Related Cardiotoxicity in Breast Cancer Patients in a One-Year Follow-Up Study. Immunol Invest 2021;:1-16. [PMID: 33557640 DOI: 10.1080/08820139.2021.1882486] [Reference Citation Analysis]
53 Radonjic T, Rankovic M, Ravic M, Zivkovic V, Srejovic I, Jeremic J, Jeremic N, Sretenovic J, Matic S, Jakovljevic V, Nikolic Turnic T. The Effects of Thiamine Hydrochloride on Cardiac Function, Redox Status and Morphometric Alterations in Doxorubicin-Treated Rats. Cardiovasc Toxicol 2020;20:111-20. [DOI: 10.1007/s12012-019-09536-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
54 Dag A, Cakilkaya E, Omurtag Ozgen PS, Atasoy S, Yigit Erdem G, Cetin B, Çavuş Kokuroǧlu A, Gürek AG. Phthalocyanine-Conjugated Glyconanoparticles for Chemo-photodynamic Combination Therapy. Biomacromolecules 2021;22:1555-67. [PMID: 33793222 DOI: 10.1021/acs.biomac.0c01811] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Petit K, Suwalsky M, Colina JR, Contreras D, Aguilar LF, Jemiola-Rzeminska M, Strzalka K. Toxic effects of the anticancer drug epirubicin in vitro assayed in human erythrocytes. Toxicol In Vitro 2020;68:104964. [PMID: 32800948 DOI: 10.1016/j.tiv.2020.104964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Altomare C, Lodrini AM, Milano G, Biemmi V, Lazzarini E, Bolis S, Pernigoni N, Torre E, Arici M, Ferrandi M, Barile L, Rocchetti M, Vassalli G. Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab. Front Physiol 2021;12:658790. [PMID: 33897465 DOI: 10.3389/fphys.2021.658790] [Reference Citation Analysis]
57 Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother 2021;139:111708. [PMID: 34243633 DOI: 10.1016/j.biopha.2021.111708] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
58 Guo Z, Tang N, Liu FY, Yang Z, Ma SQ, An P, Wu HM, Fan D, Tang QZ. TLR9 deficiency alleviates doxorubicin-induced cardiotoxicity via the regulation of autophagy. J Cell Mol Med 2020;24:10913-23. [PMID: 33140921 DOI: 10.1111/jcmm.15719] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
59 Serini S, Ottes Vasconcelos R, Nascimento Gomes R, Calviello G. Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review. Int J Mol Sci 2017;18:E2689. [PMID: 29231904 DOI: 10.3390/ijms18122689] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
60 Pizarro M, Troncoso R, Martínez GJ, Chiong M, Castro PF, Lavandero S. Basal autophagy protects cardiomyocytes from doxorubicin-induced toxicity. Toxicology 2016;370:41-8. [DOI: 10.1016/j.tox.2016.09.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
61 Saddic LA, Muehlschlegel JD. Sarco"MiR" friend or foe: a perspective on the mechanisms of doxorubicin-induced cardiomyopathy. Ann Transl Med 2016;4:203. [PMID: 27294099 DOI: 10.21037/atm.2016.05.30] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
62 Nebigil CG, Désaubry L. Updates in Anthracycline-Mediated Cardiotoxicity. Front Pharmacol 2018;9:1262. [PMID: 30483123 DOI: 10.3389/fphar.2018.01262] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 14.5] [Reference Citation Analysis]
63 Carrasco R, Castillo RL, Gormaz JG, Carrillo M, Thavendiranathan P. Role of Oxidative Stress in the Mechanisms of Anthracycline-Induced Cardiotoxicity: Effects of Preventive Strategies. Oxid Med Cell Longev 2021;2021:8863789. [PMID: 33574985 DOI: 10.1155/2021/8863789] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
64 Hirsch E. Prokineticin-izing Doxorubicin-Damaged Hearts. JACC CardioOncol 2019;1:103-4. [PMID: 34396167 DOI: 10.1016/j.jaccao.2019.08.009] [Reference Citation Analysis]
65 Carrasco R, Ramirez MC, Nes K, Schuster A, Aguayo R, Morales M, Ramos C, Hasson D, Sotomayor CG, Henriquez P, Cortés I, Erazo M, Salas C, Gormaz JG. Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled trial (CarDHA trial). Trials 2020;21:137. [PMID: 32019575 DOI: 10.1186/s13063-019-3963-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
66 Zou H, Zhu X, Ding Y, Jin Q, Qian L, Huang D, Cen X. Trimetazidine in conditions other than coronary disease, old drug, new tricks? International Journal of Cardiology 2017;234:1-6. [DOI: 10.1016/j.ijcard.2017.02.083] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
67 Gao Y, Yang H, Fan Y, Li L, Fang J, Yang W. Hydrogen-Rich Saline Attenuates Cardiac and Hepatic Injury in Doxorubicin Rat Model by Inhibiting Inflammation and Apoptosis. Mediators Inflamm 2016;2016:1320365. [PMID: 28104928 DOI: 10.1155/2016/1320365] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
68 Santos DSD, Goldenberg RCDS. Doxorubicin-Induced Cardiotoxicity: From Mechanisms to Development of Efficient Therapy. In: Tan W, editor. Cardiotoxicity. InTech; 2018. [DOI: 10.5772/intechopen.79588] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
69 Cappetta D, De Angelis A, Sapio L, Prezioso L, Illiano M, Quaini F, Rossi F, Berrino L, Naviglio S, Urbanek K. Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity. Oxid Med Cell Longev 2017;2017:1521020. [PMID: 29181122 DOI: 10.1155/2017/1521020] [Cited by in Crossref: 114] [Cited by in F6Publishing: 121] [Article Influence: 22.8] [Reference Citation Analysis]
70 Hu X, Liu H, Wang Z, Hu Z, Li L. miR-200a Attenuated Doxorubicin-Induced Cardiotoxicity through Upregulation of Nrf2 in Mice. Oxid Med Cell Longev 2019;2019:1512326. [PMID: 31781322 DOI: 10.1155/2019/1512326] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
71 Pondé NF, Lambertini M, de Azambuja E. Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open 2016;1:e000073. [PMID: 27843627 DOI: 10.1136/esmoopen-2016-000073] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
72 Narezkina A, Narayan HK, Zemljic-Harpf AE. Molecular mechanisms of anthracycline cardiovascular toxicity. Clin Sci (Lond) 2021;135:1311-32. [PMID: 34047339 DOI: 10.1042/CS20200301] [Reference Citation Analysis]
73 Sandamali JAN, Hewawasam RP, Fernando MACSS, Jayatilaka KAPW, Madurawe RD, Sathananthan PP, Ekanayake U, Horadugoda J. Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients from Southern Sri Lanka: An Echocardiographic Analysis. Biomed Res Int 2020;2020:1847159. [PMID: 33274195 DOI: 10.1155/2020/1847159] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 McLaughlin D, Zhao Y, O'Neill KM, Edgar KS, Dunne PD, Kearney AM, Grieve DJ, McDermott BJ. Signalling mechanisms underlying doxorubicin and Nox2 NADPH oxidase-induced cardiomyopathy: involvement of mitofusin-2. Br J Pharmacol 2017;174:3677-95. [PMID: 28261787 DOI: 10.1111/bph.13773] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
75 Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J, Cheng G, Lopez M, Kalyanaraman B. Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev 2017;117:10043-120. [PMID: 28654243 DOI: 10.1021/acs.chemrev.7b00042] [Cited by in Crossref: 497] [Cited by in F6Publishing: 448] [Article Influence: 99.4] [Reference Citation Analysis]
76 Nguyen N, Souza T, Verheijen MCT, Gmuender H, Selevsek N, Schlapbach R, Kleinjans J, Jennen D. Translational Proteomics Analysis of Anthracycline-Induced Cardiotoxicity From Cardiac Microtissues to Human Heart Biopsies. Front Genet 2021;12:695625. [PMID: 34211507 DOI: 10.3389/fgene.2021.695625] [Reference Citation Analysis]
77 Córdoba-Adaya JC, Oros-Pantoja R, Torres-García E, Morales-Ávila E, Aranda-Lara L, Santillán-Benítez JG, Hernández-Herrera NO, Otero G, Isaac-Olivé K. Evaluation of doxorubicin-induced early multi-organ toxicity in male CD1 mice by biodistribution of 18F-FDG and 67Ga-citrate. Pilot study. Toxicol Mech Methods 2021;31:546-58. [PMID: 34057017 DOI: 10.1080/15376516.2021.1937420] [Reference Citation Analysis]
78 Mercurio V, Pirozzi F, Lazzarini E, Marone G, Rizzo P, Agnetti G, Tocchetti CG, Ghigo A, Ameri P. Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs. J Card Fail 2016;22:449-58. [PMID: 27103426 DOI: 10.1016/j.cardfail.2016.04.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 6.3] [Reference Citation Analysis]
79 Yang Y, Wei S, Zhang B, Li W. Recent Progress in Environmental Toxins-Induced Cardiotoxicity and Protective Potential of Natural Products. Front Pharmacol 2021;12:699193. [PMID: 34305607 DOI: 10.3389/fphar.2021.699193] [Reference Citation Analysis]
80 Imosemi IO, Owumi SE, Arunsi UO. Biochemical and histological alterations of doxorubicin-induced neurotoxicity in rats: Protective role of luteolin. J Biochem Mol Toxicol 2021;:e22962. [PMID: 34766659 DOI: 10.1002/jbt.22962] [Reference Citation Analysis]
81 Chen X, Peng X, Luo Y, You J, Yin D, Xu Q, He H, He M. Quercetin protects cardiomyocytes against doxorubicin-induced toxicity by suppressing oxidative stress and improving mitochondrial function via 14-3-3γ. Toxicol Mech Methods 2019;29:344-54. [PMID: 30636491 DOI: 10.1080/15376516.2018.1564948] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
82 Diviani D, Osman H, Delaunay M, Kaiser S. The role of A-kinase anchoring proteins in cardiac oxidative stress. Biochem Soc Trans 2019;47:1341-53. [PMID: 31671182 DOI: 10.1042/BST20190228] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
83 Huang L, Zhang K, Guo Y, Huang F, Yang K, Chen L, Huang K, Zhang F, Long Q, Yang Q. Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts. Sci Rep 2017;7:11989. [PMID: 28931882 DOI: 10.1038/s41598-017-12095-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
84 Samra YA, Amin MN, Said E. Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling. Int Immunopharmacol 2021;90:107125. [PMID: 33199237 DOI: 10.1016/j.intimp.2020.107125] [Reference Citation Analysis]
85 Owumi SE, Ijadele AO, Arunsi UO, Odunola OA. Luteolin abates reproductive toxicity mediated by the oxido-inflammatory response in Doxorubicin-treated rats. Toxicology Research and Application 2020;4:239784732097204. [DOI: 10.1177/2397847320972040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
86 El Amrousy D, El-Afify D, Khedr R, Ibrahim AM. Omega 3 fatty acids can reduce early doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2021;:e29496. [PMID: 34842343 DOI: 10.1002/pbc.29496] [Reference Citation Analysis]
87 Xia W, Chen H, Xie C, Hou M. Long-noncoding RNA MALAT1 sponges microRNA-92a-3p to inhibit doxorubicin-induced cardiac senescence by targeting ATG4a. Aging (Albany NY) 2020;12:8241-60. [PMID: 32384281 DOI: 10.18632/aging.103136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
88 Sweeney M, Yiu A, Lyon AR. Cardiac Atrophy and Heart Failure In Cancer. Card Fail Rev 2017;3:62-5. [PMID: 28785478 DOI: 10.15420/cfr.2017:3:2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
89 Sivapackiam J, Kabra S, Speidel S, Sharma M, Laforest R, Salter A, Rettig MP, Sharma V. 68Ga-Galmydar: A PET imaging tracer for noninvasive detection of Doxorubicin-induced cardiotoxicity. PLoS One 2019;14:e0215579. [PMID: 31120912 DOI: 10.1371/journal.pone.0215579] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
90 Sági JC, Kutszegi N, Kelemen A, Fodor LE, Gézsi A, Kovács GT, Erdélyi DJ, Szalai C, Semsei ÁF. Pharmacogenetics of anthracyclines. Pharmacogenomics 2016;17:1075-87. [DOI: 10.2217/pgs-2016-0036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
91 Zhang Y, Ma C, Liu C, Wei F. Luteolin attenuates doxorubicin-induced cardiotoxicity by modulating the PHLPP1/AKT/Bcl-2 signalling pathway. PeerJ 2020;8:e8845. [PMID: 32435528 DOI: 10.7717/peerj.8845] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
92 Avagimyan A, Kakturskiy L, Heshmat-Ghahdarijani K, Pogosova N, Sarrafzadegan N. Anthracycline Associated Disturbances of Cardiovascular Homeostasis. Curr Probl Cardiol 2021;:100909. [PMID: 34167841 DOI: 10.1016/j.cpcardiol.2021.100909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Holmgren G, Sartipy P, Andersson CX, Lindahl A, Synnergren J. Expression Profiling of Human Pluripotent Stem Cell-Derived Cardiomyocytes Exposed to Doxorubicin—Integration and Visualization of Multi-Omics Data. Toxicological Sciences 2018;163:182-95. [DOI: 10.1093/toxsci/kfy012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]